ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,146.86
-0.21%
Dow Jones
38,535.24
-0.29%
Gold vs US Dollar
2,334.12
1.37%
Brent Oil
82.325
0.43%
Bitcoin
65,336.36
-2.13%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Dare Bioscience Inc (DARE)

  7. Dare Bioscience Inc (DARE) News

Dare Bioscience (DARE)

Dare Bioscience Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:DARE
DateTimeSourceHeadlineSymbolCompany
07/06/202422:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DAREDare Bioscience Inc
07/06/202422:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DAREDare Bioscience Inc
07/06/202422:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DAREDare Bioscience Inc
07/06/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
14/05/202421:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DAREDare Bioscience Inc
14/05/202413:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
14/05/202413:00GlobeNewswire Inc.Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company UpdateNASDAQ:DAREDare Bioscience Inc
13/05/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:DAREDare Bioscience Inc
10/05/202421:12Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:DAREDare Bioscience Inc
07/05/202413:00GlobeNewswire Inc.Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024NASDAQ:DAREDare Bioscience Inc
02/05/202413:00GlobeNewswire Inc.Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke NetworkNASDAQ:DAREDare Bioscience Inc
30/04/202412:30GlobeNewswire Inc.Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key CatalystsNASDAQ:DAREDare Bioscience Inc
23/04/202413:00GlobeNewswire Inc.Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1NASDAQ:DAREDare Bioscience Inc
11/04/202413:00GlobeNewswire Inc.Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal ContraceptiveNASDAQ:DAREDare Bioscience Inc
28/03/202412:00GlobeNewswire Inc.Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company UpdateNASDAQ:DAREDare Bioscience Inc
28/03/202411:42IH Market NewsUS Stock Futures Stable in Pre-Market On Path for Consecutive Quarterly Gains, Oil Prices RiseNASDAQ:DAREDare Bioscience Inc
21/03/202412:00GlobeNewswire Inc.Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024NASDAQ:DAREDare Bioscience Inc
22/02/202413:00GlobeNewswire Inc.Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual MeetingNASDAQ:DAREDare Bioscience Inc
31/01/202413:00GlobeNewswire Inc.Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024NASDAQ:DAREDare Bioscience Inc
29/01/202421:18Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:DAREDare Bioscience Inc
26/01/202422:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
26/01/202421:30GlobeNewswire Inc.Daré Bioscience Announces Executive Team and Board of Directors ChangesNASDAQ:DAREDare Bioscience Inc
19/01/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
17/01/202413:00GlobeNewswire Inc.Daré Bioscience Announces Grant to Support Biotherapeutic Product DevelopmentNASDAQ:DAREDare Bioscience Inc
08/01/202413:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
04/01/202413:00GlobeNewswire Inc.Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of DiseasesNASDAQ:DAREDare Bioscience Inc
26/12/202321:05Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:DAREDare Bioscience Inc
26/12/202313:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
26/12/202313:00GlobeNewswire Inc.Daré Bioscience Secures $12 million in Royalty-backed Investment StructureNASDAQ:DAREDare Bioscience Inc
20/12/202313:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
 Showing the most relevant articles for your search:NASDAQ:DARE

Your Recent History

BIT
UV4KT3
UniCredit Bank
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved